BACKGROUND: Brain-derived neurotrophic factor (BDNF) protein levels decline in the brain during senescence and are also shown to be reduced in schizophrenia patients. BDNF is present in both the gray and white matters of the brain. It is unclear whether BDNF abnormalities in schizophrenia are specific to gray and/or white matter. OBJECTIVE: We hypothesized that the age-related BDNF decline is abnormal and contributes to the reduced BDNF in schizophrenia. METHODS: We tested this hypothesis by measuring BDNF protein levels in postmortem gray and white matter, using the prefrontal cortex (PFC) and the genu of the corpus callosum as regions of interests, from 20 schizophrenia patients and 20 matched nonpsychiatric controls. Samples were selected across the adult lifespan--from 20 to 80 years of age. RESULTS: PFC gray matter BDNF protein levels were significantly lower in older age in both nonpsychiatric comparisons and patients, while BDNF in white matter did not decrease significantly with age in either group. PFC BDNF was linearly lower from 20 to 80 years of age in nonpsychiatric comparisons. In schizophrenia, the age effect was similarly linear in younger patients but a decline did not occur in older patients. CONCLUSION: PFC BDNF does not follow a normative linear age effect in schizophrenia patients as they grow older, which may represent a 'floor effect' due to earlier decline or a survivor cohort of older patient donors who are less susceptible to a schizophrenia-related pathological aging process.
BACKGROUND:Brain-derived neurotrophic factor (BDNF) protein levels decline in the brain during senescence and are also shown to be reduced in schizophreniapatients. BDNF is present in both the gray and white matters of the brain. It is unclear whether BDNF abnormalities in schizophrenia are specific to gray and/or white matter. OBJECTIVE: We hypothesized that the age-related BDNF decline is abnormal and contributes to the reduced BDNF in schizophrenia. METHODS: We tested this hypothesis by measuring BDNF protein levels in postmortem gray and white matter, using the prefrontal cortex (PFC) and the genu of the corpus callosum as regions of interests, from 20 schizophreniapatients and 20 matched nonpsychiatric controls. Samples were selected across the adult lifespan--from 20 to 80 years of age. RESULTS: PFC gray matter BDNF protein levels were significantly lower in older age in both nonpsychiatric comparisons and patients, while BDNF in white matter did not decrease significantly with age in either group. PFC BDNF was linearly lower from 20 to 80 years of age in nonpsychiatric comparisons. In schizophrenia, the age effect was similarly linear in younger patients but a decline did not occur in older patients. CONCLUSION: PFC BDNF does not follow a normative linear age effect in schizophreniapatients as they grow older, which may represent a 'floor effect' due to earlier decline or a survivor cohort of older patient donors who are less susceptible to a schizophrenia-related pathological aging process.
Authors: S J Evans; P V Choudary; C R Neal; J Z Li; M P Vawter; H Tomita; J F Lopez; R C Thompson; F Meng; J D Stead; D M Walsh; R M Myers; W E Bunney; S J Watson; E G Jones; H Akil Journal: Proc Natl Acad Sci U S A Date: 2004-10-13 Impact factor: 11.205
Authors: Da Chun Chen; Jing Wang; Bo Wang; Sheng Chang Yang; Chong Xi Zhang; You Lan Zheng; Yan Li Li; Ning Wang; Ke Bing Yang; Mei Hong Xiu; Thomas R Kosten; Xiang Yang Zhang Journal: Psychopharmacology (Berl) Date: 2009-09-29 Impact factor: 4.530
Authors: R B Dalby; B Elfving; P H P Poulsen; L Foldager; J Frandsen; P Videbech; R Rosenberg Journal: Acta Psychiatr Scand Date: 2013-01-27 Impact factor: 6.392
Authors: Hiroaki Tomita; Marquis P Vawter; David M Walsh; Simon J Evans; Prabhakara V Choudary; Jun Li; Kevin M Overman; Mary E Atz; Richard M Myers; Edward G Jones; Stanley J Watson; Huda Akil; William E Bunney Journal: Biol Psychiatry Date: 2004-02-15 Impact factor: 13.382
Authors: Ameer Y Taha; Helene C Blanchard; Yewon Cheon; Epolia Ramadan; Mei Chen; Lisa Chang; Stanley I Rapoport Journal: Mol Neurobiol Date: 2016-06-23 Impact factor: 5.590
Authors: Sasha S Binford; Erin M Hubbard; Elena Flowers; Bruce L Miller; Heather Leutwyler Journal: Biol Res Nurs Date: 2017-10-19 Impact factor: 2.522
Authors: Daniela Rodrigues-Amorim; Tania Rivera-Baltanás; Patricia Fernández-Palleiro; Marta Iglesias-Martínez-Almeida; Luis Freiría-Martínez; Cynthia Jarmardo-Rodriguez; María Del Carmen Vallejo-Curto; María Álvarez-Ariza; Marta López-García; Elena de Las Heras; Alejandro García-Caballero; José Manuel Olivares; Carlos Spuch Journal: Cell Mol Neurobiol Date: 2021-03-12 Impact factor: 5.046
Authors: Daniela Rodrigues-Amorim; Tania Rivera-Baltanás; María Del Carmen Vallejo-Curto; Cynthia Rodriguez-Jamardo; Elena de Las Heras; Carolina Barreiro-Villar; María Blanco-Formoso; Patricia Fernández-Palleiro; María Álvarez-Ariza; Marta López; Alejandro García-Caballero; José Manuel Olivares; Carlos Spuch Journal: Sci Rep Date: 2020-08-31 Impact factor: 4.379